Company newsroom

Lucid Diagnostics

NASDAQ:LUCD · NASDAQ:PAVM

2 releases

Lucid DiagnosticsNov 4, 2026

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of…

Lucid DiagnosticsNov 3, 2026

Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study

Largest peer-reviewed study of nonendoscopic esophageal precancer testing to date demonstrates the efficiency and scalability of EsoCheck® cell…